Mycophenolate Sodium API is a pharmaceutical active ingredient and immunosuppressive agent used in medicines for the prevention of organ rejection following transplantation. It is the sodium salt of mycophenolic acid and delivers mycophenolic acid as the pharmacologically active moiety. Mycophenolate Sodium belongs to the antimetabolite class of immunosuppressive medicines and is an established pharmaceutical ingredient used in transplant medicine.
Mycophenolate Sodium has the molecular formula C17H19NaO6 and a molecular weight of 342.3 g/mol. Its CAS number is 37415-62-6. It is also known as sodium mycophenolate, mycophenolic acid monosodium salt and mycophenolic acid sodium salt. The compound is listed in pharmaceutical substance databases and is recognized in the European Pharmacopoeia/British Pharmacopoeia monograph.
Mycophenolate Sodium is converted to the active moiety mycophenolic acid (MPA). MPA reversibly inhibits inosine-5'-monophosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanine nucleotides. Because activated T and B lymphocytes depend substantially on this pathway for proliferation, inhibition of IMPDH suppresses lymphocyte proliferation and contributes to the immunosuppressive effect of mycophenolate.
Mycophenolate Sodium is primarily associated with transplant medicine and immunosuppression. The FDA-approved Myfortic formulation is indicated for the prophylaxis of organ rejection in adult kidney-transplant recipients and in pediatric patients at least 5 years old who are at least 6 months post kidney transplant. It is used in combination with cyclosporine and corticosteroids.
Mycophenolate Sodium is used in the manufacture of oral pharmaceutical formulations. The FDA-approved Myfortic product is an enteric formulation of mycophenolate sodium supplied as delayed-release tablets containing 180 mg or 360 mg of mycophenolic acid. These strengths describe the finished medicinal product and should not be interpreted as API assay specifications.
The BP/Ph. Eur. monograph describes Mycophenolate Sodium as a white or almost white crystalline powder. It is slightly soluble in water and in anhydrous ethanol and very slightly soluble in heptane. The monograph also notes that Mycophenolate Sodium shows polymorphism, which can be relevant to pharmaceutical development and solid-state characterization.
The BP/Ph. Eur. monograph identifies Mycophenolate Sodium using infrared absorption spectrophotometry and a sodium identification reaction. Related substances are evaluated using liquid chromatography, with chromatographic conditions specified in the monograph for separation and quantification of impurities.
The BP/Ph. Eur. monograph specifies a content range of 98.0% to 102.0% calculated on the dried-substance basis. The assay is performed using liquid chromatography with Mycophenolate Sodium CRS as the reference standard. This provides a recognized pharmacopoeial basis for quantitative quality assessment of the API.
The BP/Ph. Eur. monograph controls related substances by liquid chromatography. It specifies a maximum of 0.10% for each unspecified impurity and a reporting threshold of 0.05%. The monograph also identifies impurities associated with the chromatographic procedure and establishes an overall total impurity limit within the specified test.
The BP/Ph. Eur. monograph specifies loss on drying of not more than 0.5%, determined by drying the substance at 105°C for 4 hours. This parameter is important for controlling moisture and volatile content in the pharmaceutical active ingredient.
Mycophenolate Sodium API is relevant to pharmaceutical formulation, analytical development, quality control and manufacturing of immunosuppressive medicines. Its established pharmacological mechanism, defined chemical identity and recognized pharmacopoeial quality requirements make it suitable for development and production activities involving transplant-related therapies.
For commercial API applications, Mycophenolate Sodium should be evaluated according to the applicable BP/Ph. Eur. or other approved pharmacopoeial standard, together with the manufacturer's validated specification and batch-specific Certificate of Analysis. Critical quality attributes can include identity, assay, related substances, loss on drying, solid-state characteristics and other applicable quality parameters.
Mycophenolate Sodium API should be stored and handled according to the applicable validated stability data, packaging requirements and manufacturer's approved specification. Storage conditions should be established from stability studies rather than assumed from generic API practices.
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 0.5% |